

Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement - "Truth in Testimony"
Required by House Rule XI, Clause 2(g)(5)

1. Your Name:	Carole Ann Heilman	
2. Your Title:	Director, Division of Microbiology and Infectious Diseases (DMID)	
3. The Entity(ies) You are Representing:	National Institutes of Health	
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No
	X	
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.		
6. Please attach your curriculum vitae to your completed disclosure form.		

Signature



Date: 11/13/2015

CAROLE A. HEILMAN, PH.D.

EDUCATION

Ph.D. in Microbiology, Rutgers University
M.S. in Microbiology, Rutgers University
B.A. (cum laude) in Biology, Boston University

PROFESSIONAL EXPERIENCE

1999 – present

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID)
DIRECTOR, DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEASES (DMID)
DR. ANTHONY S. FAUCI, M.D., DIRECTOR, NIAID

Direct \$1.5 billion research enterprise that encompasses 300 microbes and includes 2,800 grants and contracts. Establish scientific direction and oversight; manage all aspects of operations for a Division of 200 staff members. DMID supports extramural research to prevent, diagnose, and treat all human infectious agents, except HIV. This includes basic biomedical research, such as studies of microbial physiology and antigenic structure; applied research, including the development of diagnostic tests; and clinical trials to evaluate experimental drugs and vaccines.

1997 – 1999

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
DEPUTY DIRECTOR, DIVISION OF AIDS (DAIDS)
DR. JOHN Y. KILLEN, JR., M.D., DIRECTOR, DAIDS

Directed day-to-day scientific and administrative management of the Division. Developed and implemented special research projects related to emerging areas of growth and programmatic emphasis.

1996 – 1997

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
ASSOCIATE DIRECTOR FOR SCIENTIFIC PROGRAM DEVELOPMENT, DAIDS
DR. JOHN Y. KILLEN, JR., M.D., DIRECTOR, DAIDS

Developed and conducted a continuous review and evaluation of scientific operations and progress for a comprehensive research program focused on increasing knowledge of the causes, prevention, diagnosis, and treatment of HIV/AIDS and its sequelae. Directed and provided oversight of all aspects of program planning, identifying research needs and opportunities, and developing research initiatives.

1995 – 1996

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
PROGRAM COORDINATOR FOR INFECTIOUS DISEASES, DMID
DR. JOHN LA MONTAGNE, DIRECTOR, DMID

Coordinated infectious disease research including identifying research needs and opportunities, developing short- and long-term research plans, and implementing and evaluating cooperative agreements and contract programs. On behalf of the Division Director, provided oversight and scientific coordination of all branches of the Infectious Diseases Program: Respiratory Diseases Branch, Enteric Diseases Branch, and Sexually Transmitted Diseases Branch.

1989 - 1996

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
CHIEF, RESPIRATORY DISEASES BRANCH, DMID
DR. JOHN LA MONTAGNE, DIRECTOR, DMID

Coordinated, developed, and served as administrator for the Influenza and Associated Viral Respiratory Pathogen Program; two Bacterial Vaccines Programs; the Maternal Immunization and Neonatal Pathogens Program; and the Tuberculosis and Leprosy Program. Integrated work with other branches and Institutes to most efficiently and effectively meet common needs. Implemented successful management and supervisory techniques to facilitate smooth and productive interactions between program areas within the Respiratory Diseases Branch.

1988 - 1989

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
ACTING CHIEF, RESPIRATORY DISEASES BRANCH, DMID
DR. JOHN LA MONTAGNE, DIRECTOR, DMID

1986 - 1988

NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
PROGRAM OFFICER - INFLUENZA AND VIRAL RESPIRATORY DISEASES, DMID
DR. FRANKLIN TYERYAR, CHIEF, RESPIRATORY DISEASES BRANCH, DMID

Responsible for the development, coordination, and administration of the extramural program in influenza research, acute viral respiratory diseases, Reye Syndrome, and infectious diseases of the elderly. Served as Project Officer on research grants and contracts that were components of the Influenza and Acute Viral Respiratory Disease research portfolio.

1981 - 1986

NATIONAL CANCER INSTITUTE
SENIOR STAFF FELLOW, LABORATORY OF EXPERIMENTAL CARCINOGENESIS
DR. SNORRI THORGEIRSSON, CHIEF

Engaged in molecular biological research in the Laboratory of Experimental Carcinogenesis. Designed and performed experiments related to the regulation of gene expression during differentiation and neoplastic transformation. Initiated and developed the molecular biology section in the Laboratory of Experimental Carcinogenesis. This responsibility included creating strategic approaches to address questions of molecular regulation of chemically induced neoplasia as well as training and supervising post-doctoral scientists in techniques and applications of molecular biology.

1978 - 1981

NATIONAL CANCER INSTITUTE
POSTDOCTORAL RESEARCH ASSOCIATE, LABORATORY OF PATHOLOGY
DR. PETER HOWLEY, CHIEF

Postdoctoral graduate training period in the Laboratory of Pathology. Involved in the initial phases of molecular cloning and analysis of the papillomaviruses. Major research project focused on the transcriptional organization of BPV-1 in transformed and productively-infected cells. Additional responsibilities included training and supervising a technician and laboratory aide.

HONORS AND AWARDS

College of Medicine and Dentistry of New Jersey, Distinguished Alumni Award, 2011
Boston University College and Graduate School of Arts & Sciences Distinguished Alumni Award, 2010
Department of Health and Human Services, Award from Secretary for Contributions to 50 Projects in 250 Days, for work on vaccine safety and vaccine development, 2008
Department of Health and Human Services Secretary's Award for Distinguished Service for leadership in development of vaccines for biodefense, 2003
Department of Health and Human Services Secretary's Award for Distinguished Service for leadership to develop HIV/AIDS vaccines, 1999
Department of Health and Human Services Secretary's Award for Distinguished Service for leadership in development of acellular pertussis vaccine, 1996
National Institutes of Health Director's Award, 1992, 1998
National Institute of Health MERIT Award, 1990
American Cancer Society Research Fellowship Award, 1980
National Institutes of Health, Postdoctoral Fellowship Award, 1978-1980
National Research Service Award, Rutgers University, 1975-1978
General University Scholarship, Boston University, 1969-1972
WHO'S WHO, Woman Scientist

SPECIAL RECOGNITION AND PROFESSIONAL RESPONSIBILITIES

Research and Policy

Advisor, Governing Body of Translational Health Science and Technology Institute, India, 2008-present
Founding Member and Member of Board of Advisors, Lilly TB Drug Discovery Initiative, 2008-present
NIH Representative, Wellcome Trust Influenza Scientific Advisory Group, 2007-present
Scientific Board Member, Fondation Mérieux Advanced Course of Vaccinology, 2004-present
U.S. Secretariat, U.S.-Japan Cooperative Medical Sciences Program, 2000-present
U.S. Secretariat, U.S.-Indo Vaccine Action Program, 2000-present
Infectious Disease Expert, Board of Scientific Counselors, CDC, 2000-present
NIH Representative, IOM Forum on Microbial Threats, 2000-present
Advisor, WHO Initiative for Vaccine Research, 2006-2010
NIH Representative, National Vaccine Program, DHHS, 2000-2008
NIH Representative, Advisory Committee on Immunization Practices, CDC, 2000-2005
Advisor, Subcommittee on Immunology of Mycobacteria, WHO, 1994-1996
Consultant, World Bank, India/Tuberculosis Project, 1994-1995
Advisor, HCFA Influenza Demonstration Project, 1990-1991

Teaching and Mentoring

Mentor, NIH Executive Leadership Program, 2011-present
Lecturer, Johns Hopkins Bloomberg School of Public Health, Graduate Program, 2006-2011
Lecturer, Fondation Mérieux Advanced Course of Vaccinology, 2004-present
Mentor, Presidential Management Fellowship Program, 1999-2001
Preceptor, Health Scientist Administrator Training Program, 1992-1996
Staff Training in Extramural Program Committee, 1992-1995
Co-director, Fundamentals of Extramural Activity Course, 1990-1992
Women's Advisory Committee, 1987-1989
Research Advisor, University of Maryland, 1983-1985

BIBLIOGRAPHY

- Laughlin, C, Schleif, A, Heilman, C. Addressing viral resistance through vaccines. *Future Virology*. 2015; 10(8): 1011-1022.
- Heilman, C. Vaccines: An innovative approach to combating antimicrobial resistance. *Infectious Disease News*. 2015; 28(7): 8.
- Heilman, C, Engel, L, Glowinski, I. NIAID's Division of Microbiology and Infectious Diseases providing research services. *Microbe*. 2009;4(2):49.
- Sizemore, C, Heilman, C. The changing face of biomedical research in tuberculosis. *Clinical Microbiology Newsletter*. 2008;30(22):167-171.
- Landry, S, Heilman, C. Future directions in vaccines: the payoffs of basic research. *Health Affairs*. 2005;24:758-769.
- Daniels, SA, Heilman CA. NIAID - partnering with industry, academia and non-profits to prepare for, and respond to, emerging threats. *Business Briefing: Clinical Virology and Infectious Diseases*. 2005:12-13.
- Palmore, T, Folkers, G, Heilman, C, LaMontagne, JR, Fauci, A. The NIAID research agenda on biodefense. *ASM News*. 2002;68:375-382.
- Heilman, C, Baltimore, D. HIV vaccines...Where are we going? *Nature Medicine Vaccine*. 1998;Suppl 4:532-534.
- Baltimore, D, Heilman, CA. Developing an HIV vaccine. *Scientific American*. 1998;279:77-83.
- Heilman, C, Rabinovich, NR. Combination vaccines for routine infant immunization: prospects, progress and dilemmas. In Woodrow, Levine, editors. *New generation vaccines*. Marcel Dekker, Inc.; 1997. p. 619-629.
- Klein, DLK, Heilman, C. The new pertussis vaccines. In Kaufman, SHE, editor. *Concepts in vaccine development*. Walter De Gruyter & Co.; 1996. p. 89-115.
- Anderson, LJ, Heilman, C. Protective and disease-enhancing immune responses to respiratory syncytial virus. *J Infect Dis*. 1995;171:1-7.
- Maassab, H, Shaw, MW, Heilman, CA. Live influenza virus vaccine. In Plotkin, SA, Mortimer, WA Jr, editors. *Vaccines*. 2nd ed. WB Saunders Company; 1994. p. 781-801.
- Heilman, C. New approaches to vaccine delivery. In Hannoun, C, et al., editors. *Options for the control of influenza II*. Elsevier Science Publishers BV.; 1993. p. 389-391.
- Heilman, C, La Montagne, JR. Influenza: status and prospects for its prevention, therapy, and control. *Pediatric Clinics of North America*. 1990;37:669-688.
- Maassab, HF, Heilman, CA, Herlocher, ML. Cold-adapted influenza viruses for use as live vaccines for man. In Mizrahi, A, editor. *Advances in biotechnological processes: viral vaccines*. Wiley-Liss; 1990. p. 205-236.
- Heilman, CA. NIAID/WHO workshop summary: respiratory syncytial and parainfluenza viruses. *J. Infect. Dis*. 1990;161:402-406.
- Huber, BE, Heilman, CA, Thorgeirsson, SS. Poly(A+) levels of growth-differentiation-, and transformation-associated genes in the progressive development of hepatocellular carcinoma in the rat. *Hepatology*. 1989;9:756-762.

- Carole A. Heilman, Ph.D.
- Kessler, DJ, Heilman, CA, Cossman, J, Maguire, RT, Thorgeirsson, SS. Chemical transformation of EBV immortalized human B Cells. *Cancer Res.* 1987;47:527-531.
- Tosato, G, Marti, GE, Yarchoan, R, Heilman, CA, Wang, F, Pike, SE, Korsmeyer, SJ, Siminovitch, K. Epstein-Barr virus immortalization of normal cells of B Cell lineage with non-productively rearranged immunoglobulin genes. *J. Immunol.* 1986;137:2037-2042.
- Huber, BE, Heilman, CA, Wirth, PJ, Miller, MJ, Thorgeirsson, SS. Studies in gene transcription and translation in regenerating rat liver. *Hepatology.* 1986;6:209-219.
- Day, RS 3rd, Babich, MA, Yagi, T, Heilman, CA, Yarosh, DB, Scudiero, DA. The relationship of repair of O6-methylguanine to interferon action and to oncogene activation. In *Repair of DNA lesions introduced by N-nitrosocompounds.* University of Tronso, Norway: Norwegian University Press/Oxford University Press; 1985.
- Huber, BE, Dearfield, KL, Williams, JR, Heilman, CA, Thorgeirsson, SS. Tumorigenicity and transcriptional modulation of c-Myc and N-ras oncogenes in a human hepatoma cell line. *Cancer Res.* 1985;45:4322-4329.
- Thorgeirsson, UP, Turpeenniemi-Hujanen, T, Williams, JE, Westin, EH, Heilman, CA, Talmadge, JE, Liotta, LA. NIH/3T3 cells transfected with human tumor DNA containing activated Ras oncogenes express the metastatic phenotype in nude mice. *Mol. Cell. Biol.* 1985;5:259-262.
- Tosato, G, Steinberg, AD, Yarchoan, R, Heilman, CA, Pike, SE, DeSeau, V, Blaese, RM. Abnormally elevated frequency of Epstein-Barr virus-infected B Cells in the blood of patients with rheumatoid arthritis. *J. Clin. Investig.* 1984;73:1789-1795.
- Maguire, RT, Robins, TH, Thorgeirsson, SS, Heilman, CA. Expression of cellular Myc and Mos genes in undifferentiated B cell lymphomas of Burkitt and Non-Burkitt type. *Proc. Natl. Acad. Sci. USA.* 1983;80: 1947-1950.
- Engel, LW, Heilman, CA, Howley, PM. Transcriptional organization of bovine papillomavirus type 1. *J. Virol.* 1983;47:516-528.
- Heilman, CA, Engel, LW, Lowy, DR, Howley, PM. Virus specific transcription in bovine papillomavirus transformed mouse cells. *Virology.* 1982;119:22-34.
- Howley, PM, Rentier-Delrue, F, Heilman, CA, Law, MF, Chowdhury, K, Israel, MA, Takemoto, KK. Cloned human polyomavirus JC DNA can transform human amnion cells. *J. Virol.* 1980;36:878-882.
- Howley, PM, Law, MF, Heilman, CA, Engel, LW, Alonso, MC, Lancaster, WD, Israel, MA, Lowy, DR. Molecular characterization of papillomavirus genomes. In Essex, M, Todaro, G, zur Hausen, H, editors. *Viruses in naturally occurring cancers.* Cold Spring Harbor, New York: Cold Spring Harbor Laboratory; 1980. p. 233-247.
- Heilman, CA, Law, MF, Israel, MA, Howley, PM. Cloning of human papillomavirus genomic DNA's and analysis of homologous polynucleotide sequences. *J. Virol.* 1980;36:395-407.
- Heilman, CA, Rouse H. The effect of arginine starvation on the productive infection with adenovirus type 2. *Virology.* 1980;105:159-170.